

1 ARNOLD & PORTER LLP
2 MAURICE A. LEITER (State Bar No. 123732)
maury.leiter@aporter.com
3 777 South Figueroa Street, 44th Floor
Los Angeles, California 90017-5844
4 Telephone: +1 213.243.4000
Facsimile: +1 213.243.4199
5

6 ARNOLD & PORTER LLP
MICHAEL J. BAKER (State Bar No. 56492)
michael.baker@aporter.com
7 SHARON D. MAYO (State Bar No. 150469)
sharon.mayo@aporter.com
8 Three Embarcadero Center, 10th Floor
9 San Francisco, California 94111-4024
Telephone: +1 415.471.3100
10 Facsimile: +1 415.471.3400

11 *Attorneys for Defendants Bristol-Myers Squibb Company,
Sanofi-Aventis U.S. LLC, Sanofi US Services Inc.,
and Sanofi-Synthelabo Inc.*

12 [Additional Counsel Listed At Signature Page]

13
14
15 UNITED STATES DISTRICT COURT
16 NORTHERN DISTRICT OF CALIFORNIA
17 SAN FRANCISCO DIVISION

18 LAWRENCE T. EVANS *et al.*,

19 Plaintiff,

20 v.

21 BRISTOL-MYERS SQUIBB COMPANY,
22 SANOFI-AVENTIS U.S. LLC., SANOFI-
AVENTIS U.S., INC., SANOFI-
23 SYNTHELABO, INC., MCKESSON
CORPORATION, and DOES 1 to 100,

24 Defendants.

25
26
27
28

**JOINT STIPULATION AND
[PROPOSED] ORDER TO STAY
LITIGATION PENDING TRANSFER TO
THE PLAVIX® MDL**

Judge: Hon. Edward M. Chen

1 This Joint Stipulation is made by and between Plaintiffs in *Evans et al. v. Bristol-Myers*
2 *Squibb Co. et al.*, No. CV-14-2655 JSW (N.D. Cal.), and Defendants Bristol-Myers Squibb
3 Company, Sanofi-Aventis U.S. LLC, Sanofi US Services Inc., and Sanofi-Synthelabo Inc.,¹
4 (collectively “Defendants”), by and through the undersigned counsel of record, with reference to the
5 following facts:

6 1. WHEREAS, on February 12, 2013, the Judicial Panel on Multidistrict Litigation
7 (“JPML”) established a multidistrict Plavix® litigation in the District of New Jersey, assigned to
8 Judge Freda Wolfson;

9 2. WHEREAS, on June 6, 2014, Plaintiffs filed the *Evans* action in the Superior Court
10 of California, San Francisco County;

11 3. WHEREAS, on June 9, 2014, the *Evans* action was removed to this Court by
12 Defendants;

13 4. WHEREAS, on June 11, 2014, Defendants tagged this case for transfer to the
14 Plavix® MDL and anticipates that the JPML will finalize a conditional transfer order for this case
15 soon; and

16 5. WHEREAS, the Parties agree that the *Evans* action should be stayed pending its
17 anticipated transfer to the Plavix® MDL in the District of New Jersey.

18
19 THEREFORE, IT IS HEREBY STIPULATED AND AGREED, subject to the Court’s
20 approval, that the *Evans* action should be stayed pending its anticipated transfer to the Plavix®
21 MDL in the District of New Jersey.

22
23 **IT IS SO STIPULATED.**

24
25
26 ¹ Sanofi-Aventis U.S. LLC was incorrectly designated as “Sanofi-Aventis U.S. LLC,” Sanofi-
27 Aventis U.S. Inc. was incorrectly designated as “Sanofi-Aventis U.S., Inc.,” and Sanofi-Synthelabo
28 Inc. was incorrectly designated as “Sanofi-Synthelabo, Inc.” in the Complaint. As of June 11, 2012,
Sanofi-Aventis U.S. Inc. changed its name to Sanofi US Services Inc.

1 Dated: June 20, 2014

Joshua C. Ezrin
AUDET & PARTNERS, LLP
221 Main Street, Suite 1460
San Francisco, CA 94105

4 Michael Miller
5 Jeffrey A. Travers
6 THE MILLER FIRM, LLC
7 108 Railroad Avenue
Orange, VA 22960

8 By: /s/ Joshua C. Ezrin
Joshua C. Ezrin

9 *Attorney for Plaintiffs*

10 Dated: June 20, 2014

11 ARNOLD & PORTER LLP
12 Three Embarcadero Center, 10th Floor
13 San Francisco, CA 94111

14 By: /s/ Sharon D. Mayo
15 Sharon D. Mayo

16 *Attorneys for Defendants Bristol-Myers Squibb*
17 *Company, Sanofi-Aventis U.S. LLC, Sanofi US*
Services Inc., and Sanofi-Synthelabo Inc.

18
19 **PURSUANT TO STIPULATION, IT IS SO ORDERED.**

20 Date: 6/24/14



1 I, Sharon D. Mayo, am the ECF User whose ID and password are being used to file this
2 Stipulation and [Proposed] Order to Stay Litigation Pending Transfer to the Plavix® MDL. In
3 compliance with General Order 45, X.B, I hereby attest that Joshua C. Ezrin has concurred in this
4 filing.

5
6 Dated: June 20, 2014

ARNOLD & PORTER LLP

7
8 By: /s/ Sharon D. Mayo
9 Sharon D. Mayo

10 *Attorneys for Defendants Bristol-Myers Squibb
11 Company, Sanofi-Aventis U.S. LLC, Sanofi US
Services Inc., and Sanofi-Synthelabo Inc.*